Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121
July 07, 2017 08:30 ET
|
2X Oncology, Inc.
HOERSHOLM, Denmark and CAMBRIDGE, Mass., July 07, 2017 (GLOBE NEWSWIRE) -- Oncology Venture AB (“Oncology Venture”) and 2X Oncology, Inc. ("2X Oncology"), today announced that Oncology Venture has...